top of page
Research & Development
 
Department of General Surgery members participate and support residents and learners in a wide variety of research projects.
Research Projects
Many research projects are ongoing in the Department of Surgery at Health Sciences North and at the Northern Ontario School of Medicine. If you are a medical student and are interested in participating, don't hesitate to contact us!

Quality Improvement in Timeliness of EPA Completion in General Surgery Residency

QI Team: Dr Kara Nadeau, Dr Jaime Wilson, Dr Madeleine Deschenes, Dr Aruba Nurullah, Dr Jennifer MacMillan, and Dr Caitlin Cahill With the transition to Competence by Design (CBD), Entrustable Professional Activities (EPAs) have become a key component in resident evaluation. They provide essential feedback and coaching, identify challenges for early remediation, determine resident progression, and provide quality assurance of surgical training. Pre-implementation, the turnover period for completion of EPAs ranged from immediate to months after the encounter. Many were never completed at all. The feedback provided when completion is delayed is generally vague due to limited recall of the event. It has been suggested that the optimal time to evaluate EPAs is within 72 hours of the encounter, and that completion after 14 days should be excluded from assessment data (Williams et al., 2014). A pre-implementation audit at our center revealed that only 32% of EPAs were completed within 3 days of the encounter, and only 57% were completed within 14 days. A quality improvement initiative was undertaken within the General Surgery Department with the aim to improve timeliness of resident EPA completion. Multiple interventions were undertaken including an educational session, facilitation of the technological process, email and poster reminders, and personalized feedback report cards to all stakeholders. A substantial improvement in EPA timeliness was achieved, with 93% completion within 14 days of encounter. The rate of same-day completion improved from 15% to 62%, of which almost all were completed collaboratively in the presence of both the evaluator and learner. The median number of days to completion improved from 6.8 to 0.8 days. Finally, timely completion of EPAs is a key component of high-quality feedback for residents in CBD. The quality improvement initiative was successful in significantly improving timeliness at our institution and has the potential to significantly improve provision of feedback across all CBD residency programs.

Tumor RNA Disruption Assay (RDA) as a tool to assess response to neoadjuvant chemotherapy in breast cancer.

Principal investigator: Dr. Michele Brule

Co-investigators: Dr. Rachelle Paradis, Dr. Sara Rask, Dr. Silvana Spadafora

Sponsor: RNA Diagnostics Inc.

 

RDA is a test developed to predict the response of breast cancer to neoadjuvant chemotherapy even before we can notice any change on clinical examination. The RDA test is performed using a biopsy taken after the first cycle of the chemotherapy treatment. If a switch is made to a second type of chemotherapy and the tumor is still palpable, RDA will be used to assess the tumour

response to the second drug as well (using a biopsy taken after the first cycle of the new drug). When cancer cells are exposed to chemotherapy, the ribosomal RNA (rRNA) can be disrupted indicating that cancer cells are in the process of dying. RDA quantifies rRNA disruption and classifies the response to drugs into three categories: non response Zone 1, partial response Zone 2 and response Zone 3. From earlier trials, it has been shown that tumours that fall in RDA Zone 1 are unlikely to achieve a pathological Complete Response pCR (a complete eradication of cancer cells in the breast and lymph nodes). If this test is confirmed to be efficient at predicting who will not respond, it could be used in the future to tailor chemotherapy treatments for individual patients, and to help patients avoid side effects from treatments that aren’t working for their tumour. The goal of the current study is to assess the ability of RDA to predict chemotherapy response as early as ~ 14 days after

the first cycle of chemotherapy.

Factors Affecting Hepatopancreatobiliary Cancer Care Delivery in Northern Ontario

Principle Investigator: Dr. Kengo Asai

NOAMA Grant: $50000

Please reload

Recent Publications

Journals / Textbooks

Laparoscopic colectomy: trends in implementation in Canada and globally. Hoogerboord M, Ellsmere J, Caycedo-Marulanda A, Brown C, Jayaraman S, Urbach D, Cleary S. Can J Surg. 2019 Apr 1;62(2):139-141.

Transanal minimally invasive surgery for benign large rectal polyps and early malignant rectal cancers: experience and outcomes from the first Canadian centre to adopt the technique. Caycedo-Marulanda A, Jiang HY, Kohtakangas EL. Can J Surg. 2017 Dec;60(6):416-423.

Distal purse-string suture technique for TaTME. R. Wu, R. Benedict, A. Caycedo-Marulanda. Tech Coloproctol. 2019; 23(1): 67–68. Published online 2018 Dec 22. doi: 10.1007/s10151-018-1917-8.

TAMIS J-pouch excision. A. Caycedo-Marulanda, G. Ma. Tech Coloproctol. 2018; 22(12): 985–986. Published online 2018 Dec 12. doi: 10.1007/s10151-018-1905-z.

Autoimmune Pancreatitis Masquerading as Pancreatic Cancer: when in Doubt, Cut It Out. Jiang HY, Kohtakangas EL, Mitrovic B, Asai K, Shum JB. J Gastrointest Cancer. 2018 Sep;49(3):365-372. doi: 10.1007/s12029-017-9924-y. No abstract available.

Transanal total mesorectal excision (taTME) in a single-surgeon setting: refinements of the technique during the learning phase. Caycedo-Marulanda AMa GJiang HYTech Coloproctol. 2018 Jun;22(6):433-443. doi: 10.1007/s10151-018-1812-3. Epub 2018 Jun 28. 

Predictive Power of the NSQIP Risk Calculator for Early Post-Operative Outcomes After Whipple: Experience from a Regional Center in Northern Ontario. Jiang HY, Kohtakangas EL, Asai K, Shum JB.

J Gastrointest Cancer. 2018 Sep;49(3):288-294. doi: 10.1007/s12029-017-9949-2.

How Is Rectal Cancer Managed: a Survey Exploring Current Practice Patterns in Canada. Crawford AFirtell JCaycedo-Marulanda AJ Gastrointest Cancer. 2019 Jun;50(2):260-268. doi: 10.1007/s12029-018-0064-9.

Is a transanal total mesorectal excision programme feasible in a single-team setting? Caycedo-Marulanda A, Chadi S, Patel S, Knol J, Wexner SD. July 2, 2018. Colorectal Disease / Volume 20, Issue 7.

Transanal Miminally Invasive Surgery (TAMIS) and Transanal Total Mesorectal Excision (taTME). Single-Team taTME. Caycedo-Marulanda A, Ashamalla S, Ma G. pp 229-243. April 24, 2019. 

Signet Cell Adenocarcinoma with Colorectal and Facial Metastasis - A Case Report. Ryan T, Caycedo-Marulanda A. December 21, 2018. EC Gastroenterology and Digestive System Case Report: 05-11. 

bottom of page